# Progress Note 03 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Emily Dickinson (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI023-SYN
- Date: 2026-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucinda Hartwell, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Video visit four weeks after the losartan increase and dapagliflozin start. **S**

## History of present illness

Ms. Dickinson is seen by video from her home. The mobile phlebotomy service drew her blood this morning. Before the call she measured her blood pressure twice with her validated upper-arm cuff after five minutes' rest, and her weight, temperature, and oxygen saturation with her own devices; Dr. Hartwell counted her breathing on video. She has taken losartan 100 mg and dapagliflozin 10 mg daily for four weeks. She has had a headache only once in the past two weeks. She passes a little more urine and has had no lightheadedness, genital itching, or urinary symptoms. Her home blood pressure averages 138/84 over the past two weeks. She drinks to thirst, about 1.5 L a day. **S**

| Element | Detail |
|---|---|
| Visit format | Video visit from home, with home-measured vital signs and a home blood draw this morning |
| Headaches | Once in two weeks |
| Medication tolerance | No lightheadedness, genital itching, or urinary symptoms on dapagliflozin |
| Home blood pressure | Average 138/84 mmHg over two weeks |
| Fluids | About 1.5 L a day, to thirst |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Neurological | Negative | One mild headache in two weeks; no lightheadedness |
| Genitourinary | Negative | Slightly more urine; no dysuria, itching, or discharge |
| Cardiovascular | Negative | No palpitations or ankle swelling |

3 systems reviewed. **S**

## Current medications

- Losartan 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**
- Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth daily **S**
- Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a day **S**
- Dapagliflozin 10 mg oral tablet, one tablet by mouth daily **S**
- Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/84 mmHg; pulse 72 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 53.6 kg; BMI 20.2 kg/m². All vital signs are synthetic.

Sodium: 139 mmol/L; Potassium: 4.8 mmol/L; Bicarbonate (total CO2): 23 mmol/L; BUN: 23 mg/dL (high); Creatinine: 1.32 mg/dL (high); eGFR: 48 mL/min/1.73 m² (low); Glucose: 88 mg/dL. All results are synthetic.

## Change since baseline

- Sodium: 139 mmol/L at baseline, 139 mmol/L at this visit **S**
- Potassium: 4.4 mmol/L at baseline, 4.8 mmol/L at this visit **S**
- Bicarbonate (total CO2): 24 mmol/L at baseline, 23 mmol/L at this visit **S**
- BUN: 21 mg/dL at baseline, 23 mg/dL (high) at this visit **S**
- Creatinine: 1.2 mg/dL (high) at baseline, 1.32 mg/dL (high) at this visit **S**
- eGFR: 54 mL/min/1.73 m² (low) at baseline, 48 mL/min/1.73 m² (low) at this visit **S**
- Glucose: 92 mg/dL at baseline, 88 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General (video) | Comfortable and well groomed; speaking in full sentences; respiratory rate 14 counted on video |
| Extremities (video) | She pressed on both shins for five seconds: no pitting seen |
| Mental status (video) | Alert, engaged, and dryly humorous; mood "steadier" |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Chronic kidney disease G3a A2** (N18.31). Four weeks after increasing losartan and starting dapagliflozin, creatinine 1.32 mg/dL (eGFR 48) and potassium 4.8 mmol/L. The creatinine has risen about 10 percent from baseline, the expected early dip with these drugs and well within the 30 percent that is accepted. **S**
   - Continue losartan 100 mg and dapagliflozin 10 mg.
   - Urine albumin-creatinine ratio and metabolic panel at the three-month review.
   - Sick-day rules reviewed again.
2. **Hypertension with chronic kidney disease** (I12.9). 136/84 mmHg on her home cuff today and 138/84 on average, still above the KDIGO systolic target of below 120 on a maximum-dose ARB. **S**
   - Start amlodipine 5 mg daily.
   - Report ankle swelling or lightheadedness.
   - Send home readings weekly.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Potassium and creatinine after increasing the ARB and starting the SGLT2 inhibitor | 2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRA | Completed today | Potassium 4.8 mmol/L, creatinine 1.32 mg/dL, eGFR 48, four weeks after both changes |
| Examination | Standardized home blood pressure on a validated cuff | Every visit | Completed today | 136/84 mmHg today; two-week home average 138/84 |
| Examination | Weight | Every visit | Completed today | 53.6 kg on her home scale |
| Examination | Cardiac auscultation | Every visit | Deferred | Not possible at a video visit; no new cardiac symptoms. It was done three weeks after intake at the clinic visit and will be done at the home visit in June |
| Medication safety | SGLT2 inhibitor safety: volume status and genital infection | At each review after starting | Completed today | No lightheadedness or genital symptoms; fluids to thirst |
| Medication safety | Medication review: NSAID avoidance and dose adjustment | Every visit | Completed today | No NSAIDs; acetaminophen once in two weeks |
| Laboratory | Potassium and creatinine after starting amlodipine | Not required for a calcium-channel blocker | Not indicated | Amlodipine does not affect potassium or creatinine; the next panel is at the three-month review |
| Laboratory | eGFR and urine albumin-creatinine ratio | Twice a year at G3a A2 (KDIGO heat map) | Due | Next at the three-month review to judge the albuminuria response |
| Self-management | Sick-day rules | At each start of a RAAS blocker or SGLT2 inhibitor, and yearly | Completed today | Reviewed again by video |

## Goal progress

- Systolic blood pressure below 120 mmHg (KDIGO), and at least below 130/80, without lightheadedness. In progress; target 2026-09-28. **S**
- Urine albumin-creatinine ratio down by at least 30 percent from baseline on an ARB and an SGLT2 inhibitor. In progress; target 2026-06-01. **S**
- Stable kidney function, with no fall in eGFR of more than 20 percent after the expected early dip. In progress; target 2026-09-28. **S**
- 25-hydroxyvitamin D of at least 30 ng/mL. In progress; target 2026-09-28. **S**
- Care delivered at home or by video wherever safe, with clinic trips limited to tests that need the clinic. In progress; target 2026-09-28. **S**

## Medication changes

- Started: Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney Int 2024;105(4S):S117-S314)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney Int 2021;99(3S):S1-S87)
- CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026), Aether Forge

## Follow-up

- Home visit in three months with blood and urine tests; weekly home blood pressure readings by message. **S**
- Next scheduled visit 2026-06-01: home visit for the three-month kidney and blood pressure review. **S**
